Bisphosphonate-Related Osteonecrosis of the Jaws: A Review
Review Article
DOI:
https://doi.org/10.56501/intjcraniomaxillofacsurgrehab.2023.835Keywords:
Bisphosphonates, osteonecrosis, medical management, surgical managementAbstract
Bisphosphonate drugs can be used to prevent and treat osteoporosis and to reduce symptoms and complications of metastatic bone disease. However, they are associated with a rare but serious adverse event: osteonecrosis of the maxillary and mandibular bones. This condition is called bisphosphonate-related osteonecrosis of the jaw or BRONJ. Various articles have been reviewed on different treatment modalities used along with bisphosphonates, their side effects, and management. In this review article, data from different studies with different treatment modalities were carefully analyzed and drafted.
References
Rollason V, Laverriere A, MacDonald LC, Walsh T, Tramèr MR, Vogt‐Ferrier NB. Interventions for treating bisphosphonate‐related osteonecrosis of the jaw (BRONJ). Cochrane Database of Systematic Reviews. 2016(2).
Solomon DH, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporosis International. 2013 Jan;24(1):237-44.
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of oral and maxillofacial surgery. 2003 Sep 1;61(9):1115-7.
Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. Journal of oral and maxillofacial surgery. 2004 May 1;62(5):527-34.
Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. European urology. 2008 Nov 1;54(5):1066- 72.
Hasegawa T, Kawakita A, Ueda N, Funahara R, Tachibana A, Kobayashi M, Kondou E, Takeda D, Kojima Y, Sato SJ, Yanamoto S. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?. Osteoporosis International. 2017 Aug;28(8):2465-73.
Açil Y, Möller B, Niehoff P, Rachko K, Gassling V, Wiltfang J, Simon MJ. The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells. Journal of Cranio-Maxillofacial Surgery. 2012 Dec 1;40(8):e229-35.
Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treatment Reviews. 2018 Sep 1;69:177-87.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Pradeep Christopher
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
